Schrödinger takes a step forward with AlphaFold in drug R&D, as biotech hits a pipeline 'inflection'
Schrödinger has workshopped a fix for one of the biggest problems with AlphaFold-generated protein structure predictions, in what the company is describing as a notable improvement on an AI technology that’s used across biopharma.
AlphaFold is one of the most high-profile examples of AI’s impact on biology, and can generate predictions of the shape of a protein based on its amino acid sequence. But because those predictions aren’t perfect, it has limited AlphaFold’s usefulness in drug discovery — it’s been described as a “valuable hypothesis” generator, but with warnings that it can’t replace experimental data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.